Cargando…
Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?
BACKGROUND: The clinical heterogeneity of chronic rhinosinusitis (CRS) and bronchial asthma is attributable to different underlying inflammatory profiles. However, the similarity between CRS with nasal polyps (CRSwNP) and type-2 asthma pathophysiology speculates that one biological therapy could aff...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354942/ https://www.ncbi.nlm.nih.gov/pubmed/37464395 http://dx.doi.org/10.1186/s12890-023-02556-8 |
_version_ | 1785075031598956544 |
---|---|
author | Al-Ahmad, Mona Ali, Asmaa Khalaf, Mustafa Alterki, Abdulmohsen Rodriguez-Bouza, Tito |
author_facet | Al-Ahmad, Mona Ali, Asmaa Khalaf, Mustafa Alterki, Abdulmohsen Rodriguez-Bouza, Tito |
author_sort | Al-Ahmad, Mona |
collection | PubMed |
description | BACKGROUND: The clinical heterogeneity of chronic rhinosinusitis (CRS) and bronchial asthma is attributable to different underlying inflammatory profiles. However, the similarity between CRS with nasal polyps (CRSwNP) and type-2 asthma pathophysiology speculates that one biological therapy could affect both comorbidities. Despite dupilumab, a monoclonal antibody that targets IL-4α and IL-13 receptors, being used in patients with nasal polyps and severe asthma, real-life data about its efficacy in improving the quality of life and patient symptoms is still lacking. This study’s primary objective was to evaluate dupilumab treatment’s effect on the frequency of olfactory symptoms and health-related quality of life tests as measured by the Sino-nasal outcome test (SNOT-22) in patients with NP. The secondary objective was the effect of dupilumab on asthma symptom control as measured by the asthma control test (ACT). METHODS: A prospective study was conducted of 166 patients with CRSwNP, with or without asthma. The following variables were collected at baseline and after at least six months of continuous dupilumab therapy; SNOT-22, olfactory symptoms frequency, and ACT score. RESULTS: Asthma prevalence in patients with CRSwNP was high (59.63%), and being female with a history of frequent use of oral corticosteroid (OCS) courses and repeated unsuccessful nasal and para-nasal surgeries for polyposis increased the likelihood of having underlying asthma by 2, 1 and 4 times more, respectively. Additionally, being asthmatic required a longer duration of dupilumab treatment. However, both the health-related quality of life and olfactory symptoms improved equally in both groups. CONCLUSION: Even with associated comorbid asthma in patients with CRSwNP, treatment with dupilumab could improve the quality of life, olfactory symptoms, and asthma symptom control. |
format | Online Article Text |
id | pubmed-10354942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103549422023-07-20 Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference? Al-Ahmad, Mona Ali, Asmaa Khalaf, Mustafa Alterki, Abdulmohsen Rodriguez-Bouza, Tito BMC Pulm Med Research BACKGROUND: The clinical heterogeneity of chronic rhinosinusitis (CRS) and bronchial asthma is attributable to different underlying inflammatory profiles. However, the similarity between CRS with nasal polyps (CRSwNP) and type-2 asthma pathophysiology speculates that one biological therapy could affect both comorbidities. Despite dupilumab, a monoclonal antibody that targets IL-4α and IL-13 receptors, being used in patients with nasal polyps and severe asthma, real-life data about its efficacy in improving the quality of life and patient symptoms is still lacking. This study’s primary objective was to evaluate dupilumab treatment’s effect on the frequency of olfactory symptoms and health-related quality of life tests as measured by the Sino-nasal outcome test (SNOT-22) in patients with NP. The secondary objective was the effect of dupilumab on asthma symptom control as measured by the asthma control test (ACT). METHODS: A prospective study was conducted of 166 patients with CRSwNP, with or without asthma. The following variables were collected at baseline and after at least six months of continuous dupilumab therapy; SNOT-22, olfactory symptoms frequency, and ACT score. RESULTS: Asthma prevalence in patients with CRSwNP was high (59.63%), and being female with a history of frequent use of oral corticosteroid (OCS) courses and repeated unsuccessful nasal and para-nasal surgeries for polyposis increased the likelihood of having underlying asthma by 2, 1 and 4 times more, respectively. Additionally, being asthmatic required a longer duration of dupilumab treatment. However, both the health-related quality of life and olfactory symptoms improved equally in both groups. CONCLUSION: Even with associated comorbid asthma in patients with CRSwNP, treatment with dupilumab could improve the quality of life, olfactory symptoms, and asthma symptom control. BioMed Central 2023-07-18 /pmc/articles/PMC10354942/ /pubmed/37464395 http://dx.doi.org/10.1186/s12890-023-02556-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Al-Ahmad, Mona Ali, Asmaa Khalaf, Mustafa Alterki, Abdulmohsen Rodriguez-Bouza, Tito Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference? |
title | Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference? |
title_full | Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference? |
title_fullStr | Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference? |
title_full_unstemmed | Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference? |
title_short | Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference? |
title_sort | comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354942/ https://www.ncbi.nlm.nih.gov/pubmed/37464395 http://dx.doi.org/10.1186/s12890-023-02556-8 |
work_keys_str_mv | AT alahmadmona comorbidasthmainpatientswithchronicrhinosinusitiswithnasalpolypsdiddupilumabmakeadifference AT aliasmaa comorbidasthmainpatientswithchronicrhinosinusitiswithnasalpolypsdiddupilumabmakeadifference AT khalafmustafa comorbidasthmainpatientswithchronicrhinosinusitiswithnasalpolypsdiddupilumabmakeadifference AT alterkiabdulmohsen comorbidasthmainpatientswithchronicrhinosinusitiswithnasalpolypsdiddupilumabmakeadifference AT rodriguezbouzatito comorbidasthmainpatientswithchronicrhinosinusitiswithnasalpolypsdiddupilumabmakeadifference |